文献速递药物不良反应与药物警戒

生物制剂及生物类似药的安全性:现状与未来方向

Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
PubMed 文献 · Drug Saf · 2018-01-01

本文综述生物制剂及生物类似药的安全性评估现状与未来方向,聚焦上市后安全性监测。文中指出生物类似药与参照品具有相似质量、安全性和疗效,但互换性与自动替换的监管立场差异大。上市十余年未发现生物类似药与原创品安全性差异的证据,但可追溯性(品牌名和批号)在自发不良反应报告中常未落实。

要点

  • 生物类似药与参照品安全性相似,但互换性监管立场不一。
  • 上市后自发报告与理赔数据库分析对生物制剂安全性评估至关重要。
  • 不良反应报告应注明品牌名和批号以保障可追溯性。

核心结论

  • 生物类似药上市十余年未报告与原创品安全性差异的证据。
  • 互换性监管立场差异大,可追溯性要求常未落实。

研究设计与样本

  • 综述,概述生物制剂及生物类似药安全性评估特点与挑战,聚焦上市后环境。

主要发现

  • 生物类似药基于与参照品的可比性研究获批,但上市前临床疗效和安全性信息有限。
  • 互换可能引发免疫原性担忧,导致疗效缺乏和毒性。
  • 上市十余年未报告生物类似药与原创品安全性差异的证据。

关键数值与推荐

  • 生物类似药与参照品在质量、安全性和疗效上相似。
  • 自发不良反应报告应注明品牌名和批号,但该要求常未落实。

临床怎么用

  • 通过自发报告数据库和理赔数据库分析进行上市后安全性评估。
  • 在不良反应报告中记录生物制剂的品牌名和批号以保障可追溯性。

局限性

  • 上市前临床疗效和安全性信息有限,安全性评估依赖上市后数据。
  • 可追溯性要求常未落实,影响药物警戒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, marketing of highly innovative and costly biologics improved the management of high-burden diseases such as autoimmune diseases, cancers, and chronic renal failure. Several widely prescribed biologics have recently lost or will shortly lose their patents, thus opening avenues to the marketing of a growing number of biosimilars worldwide, which are products similar in terms of quality, safety, and efficacy to already licensed reference products, thus allowing for potential savings in pharmaceutical expenditure. Numerous debates about the interchangeability between biosimilars and reference products are still ongoing, owing to concerns about potential immunogenicity raised by switching, which may cause a lack of effect and toxicity. Patients successfully treated with biologic therapy may theoretically receive biosimilars to contain costs, if reference product and related biosimilar are judged as interchangeable. However, the positions of regulatory agencies on the interchangeability and automatic substitution of biologics with biosimilars are very different. The benefit-risk profile of biosimilars has been often questioned by clinicians owing to the limited amount of pre-marketing information on clinical efficacy and safety, despite biosimilarity being based on a comparability exercise with the reference product to gain the biosimilar approval. Nevertheless, after more than 10 years of marketing from the first biosimilar approval in Europe, no proof of differences in terms of the safety profile of biosimilars and originators has been reported. In this context, post-marketing evaluation of both biologics and biosimilars safety profiles through analyses from spontaneous reporting databases and claims databases is crucial. An important issue for the pharmacovigilance of biologics concerns the traceability, indicating the brand name and batch number in spontaneous adverse drug reaction reports, but this requirement is not frequently addressed. This review aims to provide an overview of the characteristics and potential challenges in the safety profile assessment of biologics with a focus on the post-marketing setting.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Ingrasciotta Y, Cutroneo PM, Marcianò I, et al. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Saf. 2018. PMID: 29796832. doi:10.1007/s40264-018-0684-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。